RT Journal Article
SR Electronic
T1 Leveraging patients’ longitudinal data to improve the Hospital One-year Mortality Risk
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.21.24309191
DO 10.1101/2024.06.21.24309191
A1 Laribi, Hakima
A1 Raymond, Nicolas
A1 Taseen, Ryeyan
A1 Poenaru, Dan
A1 Vallières, Martin
YR 2024
UL http://medrxiv.org/content/early/2024/06/21/2024.06.21.24309191.abstract
AB Objective To develop and validate an Ensemble Long Short-term Memory neural network (ELSTM) that integrates patients’ longitudinal data to predict the Hospital One-year Mortality Risk using patients’ information collected routinely at admission. The aim is to identify patients at the end of life who may benefit from goals of care (GOC) discussions.Materials and Methods We evaluated our ELSTM (i) when including only predictors that can be reported upon admission (Ad-mDemo), and (ii) when adding also diagnoses available later during patients’ stay (AdmDemoDx). We used records of 82,104 patients admitted between 2011 and 2017 to compare the temporal and non-temporal strategies. We also quantified the clinical utility of the best strategy on 33,898 patients eligible for GOC discussions admitted between 2017 and 2021.Results Our ELSTM used with AdmDemo and AdmDemoDx predictors demonstrated an increased performance with AUROCs between 0.73-0.90 and 0.79-0.93, respectively. The ELSTM-based decision-making increased prediction precision by up to 12.1% compared to the usual decision-making process, but it also reduced sensitivity by up to 3.8%.Discussion The integration of patients’ longitudinal data provides better insights into the severity of illness and the overall condition of patients, especially when limited information is available during their hospitalization.Conclusion The proposed ELSTM is an automated and accurate model able to identify patients at high risk of one-year mortality, potentially usable in clinical decision support systems to improve end-of-life care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by : (i) Canada CIFAR AI Chair, Mila; (ii) Natural Sciences and Engineering Research Council of Canada (NSERC), Discovery Grants Program (RGPIN-2021-03996); (iii) Fonds de recherche du Quebec - Nature et technologies, programme releve professorale (312290).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of the Centre integré universitaire de santé et de services sociaux de lEstrie - Centre hospitalier universitaire de Sherbrooke project Nagano #2022-4409 gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes